Squamous cell carcinoma of head and neck

48 trials 15 recruiting MedDRA PT
48 Registered trials
15 Recruiting
36 Unique sponsors
52 Unique IMPs
36 Commercial trials
Drug classes (ATC)
— ATC code not specified 28
L Oncology (ATC L) 20
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 22 substances
Kinase inhibitor 5 substances
Antimetabolite 3 substances
Checkpoint inhibitor (PD-1) 2 substances
Monoclonal antibody (immune) 2 substances
Checkpoint inhibitor (PD-L1) 2 substances
Receptor fusion protein 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Alkylating agent 1 substance
PARP inhibitor 1 substance
Taxane 1 substance
RAF/BRAF inhibitor 1 substance
BCL-2 inhibitor 1 substance
Monoclonal antibody (angiogenesis) 1 substance
Anthracycline 1 substance
SERD 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Antibody-drug conjugate (ADC) 1 substance
Monoclonal antibody 1 substance
Monoclonal antibody (chimeric) 1 substance
Platinum compound 1 substance
Checkpoint inhibitor (CTLA-4) 1 substance
Phase III: 6 Phase II/III: 3 Phase II: 11 Phase I/II: 5 Phase I: 16 Phase I (Other): 2 Phase I (First in Human): 5

Filter these 48 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 48 trials

Phase III

6 trials
  • F. Hoffmann-La Roche AG Commercial
    ALECTINIB; ALECTINIB HYDROCHLORIDE; ATEZOLIZUMAB; CABOZANTINIB; COBIMETINIB; NIRAPARIB; PACLITAXEL; PEMETREXED; SUNITINIB; VEMURAFENIB; VENETOCLAX
    2023-506184-34-00 11 countries 2019 n=104 Orphan
    Ended
  • Glaxosmithkline Research & Development Limited Commercial
    DOSTARLIMAB
    2023-508613-17-00 13 countries 2024 n=364
    Recruiting
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB
    2022-500254-41-00 9 countries 2018 n=175
    Ended
  • European Organisation For Research And Treatment Of Cancer Academic
    IMP not specified
    2023-504478-39-00 3 countries 2025 n=160
    Recruiting
  • Groupe Oncologie Radiotherapie Tete Cou Academic
    AVELUMAB; CETUXIMAB; CISPLATIN
    2024-513964-24-00 1 country 2017 n=706
    Ended
  • Groupe Oncologie Radiotherapie Tete Cou Academic
    CISPLATIN
    2024-513972-16-00 2 countries 2017 n=342
    Ended

Phase II/III

3 trials
  • BioNTech SE Commercial
    RBL015.2, RBL016.2
    2024-512671-12-00 11 countries 2021 n=98
    Recruiting
  • Exelixis Inc. Commercial
    N-(4-FLUOROPHENYL)-N-(4-((7-METHOXY-6-(METHYLCARBAMOYL)QUINOLIN-4- YL)OXY)PHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE; PEMBROLIZUMAB
    2023-506308-24-00 13 countries 2024 n=112
    Recruiting
  • Inhibrx Biosciences Inc. Commercial
    HUMAN IGG1 HEXAVALENT ANTIBODY AGAINST TNFRSF4; PEMBROLIZUMAB
    2024-515538-34-00 7 countries 2025 n=175
    Ended

Phase II

11 trials
  • Alx Oncology Inc. Commercial
    EVORPACEPT; PEMBROLIZUMAB
    2023-508340-22-00 3 countries 2021 n=50
    Ended
  • Alx Oncology Inc. Commercial
    EVORPACEPT; PEMBROLIZUMAB
    2023-508342-17-00 3 countries 2021 n=55
    Ended
  • Ascendis Pharma Oncology Division A/S Commercial
    ACP-017; PEMBROLIZUMAB; TRANSCON IL-2Β/Γ
    2023-506092-10-00 5 countries 2024 n=43
    Ended
  • BeOne Medicines AG Commercial
    LBL-007; SURZEBICLIMAB; TISLELIZUMAB
    2023-503418-63-00 3 countries 2023 n=28
    Ended
  • Dualitybio Inc. Commercial
    BNT324; BNT327; HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST TROP2 CONJUGATED TO N-((7S,15S)-7-BENZYL-17-(((1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL-10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12H-BENZO[DE]PYRANO[3',4':6,7] INDOLIZINO[1,2-B]QUINOLIN-1-YL)AMINO)-15-METHYL-2,5,8,11,17-PENTAOXO-14-OXA-3,6,9,12-TETRAAZAHEPTADECYL)-6-(2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-1-YL)HEXANAMIDE
    2025-523895-22-00 5 countries n=102
    Pending
  • Glaxosmithkline Research & Development Limited Commercial
    DOSTARLIMAB; GSK4381562A; GSK6097608; HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST TIGIT
    2023-503428-24-00 12 countries 2024 n=232
    Ended
  • IO Biotech ApS Commercial
    IO103 ACETATE; PEMBROLIZUMAB
    2022-502787-20-00 4 countries 2023 n=65
    Ended
  • Iovance Biotherapeutics Inc. Commercial
    AUTOLOGOUS TUMOUR-INFILTRATING LYMPHOCYTES; CYCLOPHOSPHAMIDE; FLUDARABINE PHOSPHATE; LIFILEUCEL; PEMBROLIZUMAB
    2024-510779-39-00 3 countries 2018 n=95
    Ended
  • Cliniques Universitaires Saint-Luc Academic
    IO102 HYDROCHLORIDE; IO102 HYDROCHLORIDE, IO103 ACETATE; IO103 ACETATE
    2024-513447-82-00 1 country n=39
    Ended
  • European Organisation For Research And Treatment Of Cancer Academic
    XEVINAPANT
    2022-502339-20-00 9 countries 2023 n=225
    Ended
  • Groupe Oncologie Radiotherapie Tete Cou Academic
    DURVALUMAB
    2024-513977-31-00 1 country 2019 n=61
    Ended

Phase I/II

5 trials
  • Amgen Inc. Commercial
    BEMARITUZUMAB
    2023-505455-44-00 15 countries 2022 n=300
    Ended
  • Daiichi Sankyo Inc. Commercial
    IFINATAMAB DERUXTECAN
    2023-509632-26-00 9 countries 2025 n=311 Orphan
    Recruiting
  • Nykode Therapeutics ASA Commercial
    PEMBROLIZUMAB; VB10.16
    2022-503055-26-00 7 countries 2023 n=78
    Recruiting
  • Grupo Espanol De Tratamiento De Tumores De Cabeza Y Cuello Academic
    DOSTARLIMAB; NIRAPARIB
    2024-516779-33-00 1 country 2023 n=34
    Ended
  • Institut Gustave Roussy Academic
    DURVALUMAB; TREMELIMUMAB
    2024-514920-18-00 1 country 2017 n=61
    Ended

Phase I

16 trials
  • AstraZeneca AB Commercial
    IMP not specified
    2022-501570-18-00 3 countries 2023 n=145
    Ended
  • Beigene Ltd. Commercial
    IMP not specified
    2023-503996-38-00 1 country 2025 n=60
    Ended
  • Beigene Ltd. Commercial
    IMP not specified
    2023-505322-34-00 1 country 2024 n=45
    Ended
  • BeOne Medicines AG Commercial
    IMP not specified
    2023-506888-34-00 1 country 2024 n=91
    Recruiting
  • Incyte Corp. Commercial
    IMP not specified
    2022-501505-13-00 4 countries 2023 n=140
    Ended
  • Janssen - Cilag International Commercial
    IMP not specified
    2025-521535-36-00 1 country 2025 n=52
    Recruiting
  • Merck Healthcare KGaA Commercial
    IMP not specified
    2025-523232-39-00 1 country n=14
    Pending
  • Merck Sharp & Dohme LLC Commercial
    IMP not specified
    2024-516870-31-00 1 country 2025 n=21
    Recruiting
  • Novartis Pharma AG Commercial
    IMP not specified
    2022-502381-25-01 4 countries 2024 n=97
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2024-514745-10-00 5 countries 2025 n=58
    Ended
  • Seagen Inc. Commercial
    IMP not specified
    2023-506604-18-00 6 countries 2024 n=177
    Recruiting
  • Tenboron Oy Commercial
    IMP not specified
    2024-517779-19-00 1 country 2024 n=6
    Ended
  • Incyte Corp. Academic
    IMP not specified
    2023-504400-29-00 1 country 2022 n=9
    Ended
  • Karolinska University Hospital Academic
    IMP not specified
    2023-508126-95-00 1 country 2025 n=30
    Recruiting
  • Novartis Pharma AG Academic
    IMP not specified
    2022-500540-38-00 5 countries 2023 n=88
    Ended
  • Regeneron Pharmaceuticals Inc. Academic
    IMP not specified
    2022-500868-36-00 1 country 2021 n=19
    Ended

Phase I (Other)

2 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IMP not specified
    2023-506227-29-00 2 countries 2024 n=60
    Recruiting
  • Janssen - Cilag International Commercial
    IMP not specified
    2025-522914-22-00 1 country 2026 n=8
    Recruiting

Phase I (First in Human)

5 trials
  • Alentis Therapeutics AG Commercial
    ALE.C04; PEMBROLIZUMAB
    2023-505145-93-00 3 countries 2024 n=104
    Ended
  • Beigene Ltd. Commercial
    LBL-007; SURZEBICLIMAB; TISLELIZUMAB
    2022-500694-14-00 4 countries 2023 n=48
    Ended
  • Exscientia AI Limited Commercial
    BEVACIZUMAB; CAPECITABINE; DOXORUBICIN HYDROCHLORIDE; FULVESTRANT; GTAEXS617; PACLITAXEL
    2023-508227-13-00 1 country 2023 n=112
    Recruiting
  • Pathios Therapeutics Limited Commercial
    NIVOLUMAB; PTT-4256
    2025-522944-41-00 2 countries n=95
    Pending
  • Transgene Commercial
    IMP not specified
    2023-508561-33-00 2 countries 2019 n=98
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Beigene Ltd. Commercial 3 Phase I, Phase I (First in Human) 0
Groupe Oncologie Radiotherapie Tete Cou Academic 3 Phase II, Phase III 0
BeOne Medicines AG Commercial 2 Phase I, Phase II 1
Incyte Corp. Commercial 2 Phase I 0
Janssen - Cilag International Commercial 2 Phase I, Phase I (Other) 2
Merck Sharp & Dohme LLC Commercial 2 Phase I, Phase III 1
Novartis Pharma AG Commercial 2 Phase I 0
Alx Oncology Inc. Commercial 2 Phase II 0
Glaxosmithkline Research & Development Limited Commercial 2 Phase II, Phase III 1
European Organisation For Research And Treatment Of Cancer Academic 2 Phase II, Phase III 1
AstraZeneca AB Commercial 1 Phase I 0
Merck Healthcare KGaA Commercial 1 Phase I 0
Pfizer Inc. Commercial 1 Phase I 0
Seagen Inc. Commercial 1 Phase I 1
Tenboron Oy Commercial 1 Phase I 0
BioNTech SE Commercial 1 Phase II/III 1
Exelixis Inc. Commercial 1 Phase II/III 1
Inhibrx Biosciences Inc. Commercial 1 Phase II/III 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase I (Other) 1
Ascendis Pharma Oncology Division A/S Commercial 1 Phase II 0
New trials by year
2019
3
2021
4
2022
2
2023
10
2024
11
2025
8
2026
1
← All indication landscapes